COVID-19 Testing at Laboratories: Questions and Answers

Updated March 10, 2020

CDC provides the test kits for public health laboratories (PHLs) to perform real-time RT-polymerase chain reaction (rRT-PCR) detection of the SARS-CoV-2 virus (the virus that causes COVID-19) in respiratory specimens. CDC received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) on February 4, 2020 for use of this rRT-PCR test to detect the virus in upper and lower respiratory specimens.  These test kits are available through the International Reagent Resource (IRR)external iconexternal icon.  For over ten years, CDC has provided test kits and reagents to PHLs through the IRR.  This resource was established to support state and local public health laboratories, Department of Defense laboratories, and other qualified laboratories participating in public health surveillance and studies.  Clinical and commercial laboratories conducting COVID-19 testing access test reagents from commercial reagent manufacturers which have received EUA from the FDA. Genomic RNA material for validation purposes can be obtained from BEI Resources as indicated in question 7 below.

The International Reagent Resource (IRR) was established by the Centers for Disease Control and Prevention (CDC) to provide registered users with reagents, tools and information for studying and detection of Influenza and other pathogens, including the SARS-CoV-2 virus that causes Coronavirus Disease 2019 (COVID-19). The IRR acquires, authenticates, and produces reagents that scientists need to carry out basic research and develop improved diagnostic tests, vaccines, and detection methods.  By centralizing these functions within the IRR, access to and use of these materials in the scientific and public health community is monitored and quality control of the reagents is assured.  The International Reagent Resourceexternal iconexternal icon is managed under a CDC contract by American Type Culture Collection (ATCC).

Public health laboratories in the U.S. performing COVID-19 testing of respiratory specimens are provided the following reagents from the CDC’s International Reagent Resource (IRR):

  • Equipment and Extraction Kits – These kits are used in the preparation of specimens
    • QIAGEN with QIAmp DSP Viral RNA Mini Kit (obtained from IRR)
    • QIAGEN EZ1 Advanced XL with EZ1 DSP Virus Kit (obtained from IRR)
    • QIAGEN QIAcube with QIAmp DSP Viral RNA Mini Kit (obtained from IRR))
    • Roche MagNA Pure LC with Total Nucleic Acid Kit
    • Roche MagNA Pure Compact with Nucleic Acid Isolation Kit I
    • Roche MagNA Pure 96 with DNA and Viral NA Small Volume Kit
  • rRT-PCR Test Kits (CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel) – These kits include vials of test reagents that detect the virus that causes COVID-19 in respiratory specimens (obtained from IRR)
  • Reagents –
    • Master Mix Kits (rRT-PCR Enzyme Mastermix (TaqPath™ 1-Step RT-qPCR Master Mix, CG) – These kits contain the enzymes and other components needed to run the PCR test. (obtained from IRR)
    • Human Specimen Control (HSC) (obtained from IRR)
    • EUA Positive Control (obtained from IRR)

FDA

  • Currently, genomic RNA material can be used for validation purposes at biosafety level 2 laboratories (BSL-2). Genomic RNA material is available through BEI Resourcesexternal iconexternal iconRegistrationexternal iconexternal icon with BEI Resources is required to request SARS-CoV-2 materials.BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations with a 12 to 72-hour turnaround time for all SARS-CoV-2 related registrations.  Please contact BEI Resources at contact@beiresources.org or 1-800 359-7370 for questions.
  • Developers are required to sign a material transfer agreement prior to the release of materials.
  • All BEI Resources reagents are provided worldwide. There is no cost for the reagents themselves. However, shipping and handling charges may apply.
  • If a kit to detect the virus (SAR-CoV-2) is needed, then contact IRR as indicated in FAQ#1 above.

BEI Resources Repositoryexternal iconexternal icon was established by the National Institute of Allergy and Infectious Diseasesexternal iconexternal icon at the National Institutes of Health to provide reagents, tools and information for studying Category A, B, and Cexternal iconexternal icon priority pathogens, emerging infectious diseaseexternal iconexternal icon agents, non-pathogenic microbes and other microbiological materials of relevance to the research community including diagnostic developers.  Centralizing these functions within BEI Resources facilitates access to these materials by the scientific community and ensures quality control of the reagents.